Zepatier: Difference between revisions

Line 11:

== Function ==

Zepatier is a combination drug combating genotypes 1 and 4 of chronic hepatitis C viral (HCV) infections in adults. It is designed for the treatment of individuals with end stage renal disease on dialysis, typically genotype 1 infected patients. The drug is also utilized to treat genotype 4 patients when other methods of treatment prove ineffective <ref>Petrescu, I. O.; Biciusca, V.; Taisescu, C. I.; Alexandru, D. O.; Taisescu, O.; Comanescu, M. V.; Petrescu, F.; Popescu, I. A.; Trasca, D. M.; ForTofoiu, M. C.; Silosi, C. A.; ForTofoiu, M. To see an example of the ~~NCV~~ genome, click here [https://www.ncbi.nlm.nih.gov/books/NBK1630/figure/ch1.f2/?report=objectonly]. Histological factors that predict the liver fibrosis in patients with chronic hepatitis C. Rom. J. Morphol. Embryol. 2016, 57, 759-765.</ref>.<scene name='74/746120/Elbasvir_structure3/1'>Elbasvir</scene> inhibits NS5A, a non-enzymatic protein essential for viral replication and assembly of hepatitis C whose exact mechanism of action is unknown. Elbasvir restricts viral production at the early stage of assembly, in turn preventing spread of the virus<ref name="elbasvir">DOI: 10.1002/cmdc.201300343</ref>.

Zepatier is a combination drug combating genotypes 1 and 4 of chronic hepatitis C viral (HCV) infections in adults. It is designed for the treatment of individuals with end stage renal disease on dialysis, typically genotype 1 infected patients. The drug is also utilized to treat genotype 4 patients when other methods of treatment prove ineffective <ref>Petrescu, I. O.; Biciusca, V.; Taisescu, C. I.; Alexandru, D. O.; Taisescu, O.; Comanescu, M. V.; Petrescu, F.; Popescu, I. A.; Trasca, D. M.; ForTofoiu, M. C.; Silosi, C. A.; ForTofoiu, M. To see an example of the HCV genome, click here [https://www.ncbi.nlm.nih.gov/books/NBK1630/figure/ch1.f2/?report=objectonly]. Histological factors that predict the liver fibrosis in patients with chronic hepatitis C. Rom. J. Morphol. Embryol. 2016, 57, 759-765.</ref>.<scene name='74/746120/Elbasvir_structure3/1'>Elbasvir</scene> inhibits NS5A, a non-enzymatic protein essential for viral replication and assembly of hepatitis C whose exact mechanism of action is unknown. Elbasvir restricts viral production at the early stage of assembly, in turn preventing spread of the virus<ref name="elbasvir">DOI: 10.1002/cmdc.201300343</ref>.

<scene name='74/746120/Grazoprevir_meg/1'>Grazoprevir</scene> is a macrocyclic compound that is able to reversibly bind to the protease, NS3/4A, essential for viral replication. It is responsible for cleavage and processing of the HCV polyprotein. It is hypothesized that the protease is utilized to circumvent immune response at the primary stages of infection <ref>DOI: 10.1021/acschembio.5b00647</ref>.

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 11: / Line 11: @@
 == Function ==
-Zepatier is a combination drug combating genotypes 1 and 4 of chronic hepatitis C viral (HCV) infections in adults. It is designed for the treatment of individuals with end stage renal disease on dialysis, typically genotype 1 infected patients. The drug is also utilized to treat genotype 4 patients when other methods of treatment prove ineffective <ref>Petrescu, I. O.; Biciusca, V.; Taisescu, C. I.; Alexandru, D. O.; Taisescu, O.; Comanescu, M. V.; Petrescu, F.; Popescu, I. A.; Trasca, D. M.; ForTofoiu, M. C.; Silosi, C. A.; ForTofoiu, M. To see an example of the NCV genome, click here [https://www.ncbi.nlm.nih.gov/books/NBK1630/figure/ch1.f2/?report=objectonly]. Histological factors that predict the liver fibrosis in patients with chronic hepatitis C. Rom. J. Morphol. Embryol. 2016, 57, 759-765.</ref>.<scene name='74/746120/Elbasvir_structure3/1'>Elbasvir</scene> inhibits NS5A, a non-enzymatic protein essential for viral replication and assembly of hepatitis C whose exact mechanism of action is unknown. Elbasvir restricts viral production at the early stage of assembly, in turn preventing spread of the virus<ref name="elbasvir">DOI: 10.1002/cmdc.201300343</ref>.
+Zepatier is a combination drug combating genotypes 1 and 4 of chronic hepatitis C viral (HCV) infections in adults. It is designed for the treatment of individuals with end stage renal disease on dialysis, typically genotype 1 infected patients. The drug is also utilized to treat genotype 4 patients when other methods of treatment prove ineffective <ref>Petrescu, I. O.; Biciusca, V.; Taisescu, C. I.; Alexandru, D. O.; Taisescu, O.; Comanescu, M. V.; Petrescu, F.; Popescu, I. A.; Trasca, D. M.; ForTofoiu, M. C.; Silosi, C. A.; ForTofoiu, M. To see an example of the HCV genome, click here [https://www.ncbi.nlm.nih.gov/books/NBK1630/figure/ch1.f2/?report=objectonly]. Histological factors that predict the liver fibrosis in patients with chronic hepatitis C. Rom. J. Morphol. Embryol. 2016, 57, 759-765.</ref>.<scene name='74/746120/Elbasvir_structure3/1'>Elbasvir</scene> inhibits NS5A, a non-enzymatic protein essential for viral replication and assembly of hepatitis C whose exact mechanism of action is unknown. Elbasvir restricts viral production at the early stage of assembly, in turn preventing spread of the virus<ref name="elbasvir">DOI: 10.1002/cmdc.201300343</ref>.
 <scene name='74/746120/Grazoprevir_meg/1'>Grazoprevir</scene> is a macrocyclic compound that is able to reversibly bind to the protease, NS3/4A, essential for viral replication. It is responsible for cleavage and processing of the HCV polyprotein. It is hypothesized that the protease is utilized to circumvent immune response at the primary stages of infection <ref>DOI: 10.1021/acschembio.5b00647</ref>.